<DOC>
	<DOCNO>NCT02803333</DOCNO>
	<brief_summary>The Moffitt Cancer Center PatientsLikeMe.com ( PLM ) , online patient community , work together well understand patient 's entire lung cancer experience , inside outside doctor 's office . By combine data capture care team clinic data participant enter home PatientsLikeMe.com , investigator hope improve patient-physician treatment decision , patient 's personal treatment goal quality life high chance fulfil .</brief_summary>
	<brief_title>Oncology Research Information Exchange Network ( ORIEN ) Lung Cancer Study</brief_title>
	<detailed_description>The aim study ass real-world patient experience evaluate patient ' quality life , treatment toxicity , clinical measure 6-month period . The ultimate goal research improve patient-physician treatment decision , patient 's personal treatment goal quality life high chance fulfil . Aim 1 . To track toxicities/side-effects FDA approve molecular targeted agent , immunotherapy , combination treatment NSCLC clinical set six month . Aim 2 . To assess impact treatment regimens patient toxicity , symptom , function , quality life , adjustment clinical factor patient characteristic 6 month follow-up period .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>&gt; = 18 year age Diagnosed metastatic ( stage 3b/4 ) nonsmall cell lung cancer ( NSCLC ) The total combined sample size must include least 100 people receive one treatment PD1/PDL1 inhibitor treatment ( immunotherapy ) , 50 patient receive Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ( EGFRTKI ) . Patients receive treatment track treatment outcome , well serve comparison participant data analysis outcomes associate PD1/PDL1 EGFRTKI ) . Consented separately Total Cancer Care ( TCC ) protocol Have access internet Willing enroll free online health track patient community `` PatientsLikeMe '' Patients enrol Phase I clinical trial protocol Patients enrol Phase II , III IV clinical trial involve blinded therapy ( patient open label trial eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Thoracic Neoplasms</keyword>
</DOC>